A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma

Nina D. Wagner-Johnston, Andrè Goy, Maria A. Rodriguez, W. Christopher Ehmann, Paul A. Hamlin, John Radford, Catherine Thieblemont, Cheolwon Suh, John Sweetenham, Yifan Huang, Sharon T. Sullivan, Erik R. Vandendries, Christian Gisselbrecht

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences